Proposed $A_2C_2S_2$-VASc score for predicting atrial fibrillation development in patients with atrial flutter

Yung-Lung Chen 1,2, Hui-Ting Wang,3 Huang-Chung Chen,1 Wen-Hao Liu,1 Shaur-Zheng Chong,1 Shu-Kai Hsueh,1 Chang-Ming Chung,3 Yu-Shen Lin 4

ABSTRACT

Aims The clinical outcome and threshold of oral anticoagulation differs between patients with solitary atrial flutter (AFL) and those with AFL developing atrial fibrillation (AF) (AFL-DAF). We therefore investigated previously unvalidated predictors of AF development in patients with AFL, and also the predictive values of risk scores in predicting the occurrence of AF and ischaemic stroke.

Methods and results Participants were those diagnosed with AFL between 1 January 2001 and 31 December 2013. Patients were classified into solitary AFL and AFL-DAF groups during follow-up. Finally, 4101 patients with solitary AFL and 4101 patients with AFL-DAF were included after 1:1 propensity score matching with CHA2DS2-VASc scores and their components, AFL diagnosis year and other comorbidities. The group difference in the prevalence of ischaemic stroke/transient ischaemic attack (TIA) and congestive heart failure (CHF) was substantial, that of vascular disease was moderate, and that of diabetes and hypertension was negligible. Therefore, we reweighted the component of heart failure as 2 (the same with stroke/TIA) and vascular disease as 1 in the proposed $A_2C_2S_2$-VASc score. The proposed $A_2C_2S_2$-VASc and CHA2DS2-VASc scores showed patients with AFL who had higher delta scores and follow-up scores had higher risk of AF development. The delta score outperformed the follow-up score in both scoring systems in predicting ischaemic stroke.

Conclusion This study showed that new-onset CHF, stroke/TIA and vascular disease were predictors of AF development in patients with AFL. The dynamic score and changes in both CHA2DS2-VASc and the proposed $A_2C_2S_2$-VASc score could predict the development of AF and ischaemic stroke.

INTRODUCTION

Solitary atrial flutter (AFL) and AFL developing into atrial fibrillation (AF) (AFL-DAF) contribute to different levels of mortality, stroke and heart failure (HF).1–4 In addition, the threshold of initiation of oral anticoagulation (OAC) to prevent stroke, transient ischaemic attack (TIA) and systemic embolism also differed among these patients.3 4 Hence, it would be important to be able to predict those patients with AFL who will develop AF during follow-up. The CHA2DS2-VASc score (HF, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65–74 and sex category (female)) has been the most commonly used risk score to predict stroke, and its application has been extended to predicting endpoints other than stroke.5 6 A previous study reported that the CHA2DS2-VASc score could also be used to predict the occurrence of AF and ischaemic stroke after cavotricuspid isthmus (CTI) ablation for AFL.7 8 Besides, the dynamic changes in the CHA2DS2-VASc score due to ageing and the new onset of comorbidities should be a concern in predicting the development of AF during follow-up. In addition, the weight of the predicting power of each component of CHA2DS2-VASc is equal, or may differ with time, so this may be another interesting issue. Therefore, determining the best scoring system to predict the development of AF in patients with AFL among the CHA2DS2-VASc,
the adjusted CHA\textsubscript{DS}\textsubscript{2}-VASc and even among changes between baseline and the point at which AF is diagnosed is an interesting issue. In this study, we compared these different scores to predict the new development of AF in patients with AFL using a large-scale national cohort.

METHODS

Data source

This national cohort study used data on patients with AFL retrieved from Taiwan’s National Health Insurance Research Database (NHIRD) from 1 January 2001 to 31 December 2013. The NHIRD is part of Taiwan’s National Health Insurance programme, which is a compulsory single-payer healthcare system covering more than 20 million Taiwanese, and contains healthcare information dating back to 1997. The NHIRD includes data on any outpatient visits, hospitalisation, drug prescriptions, comorbidities and vital status. The identifying data of all participants have been encrypted to protect their privacy, but the participants can be longitudinally followed since the encrypting procedure was consistent. Diseases were identified using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes (online supplemental table 1). Our study population was coded as 427.32, those who were diagnosed as having AFL in consecutive clinics or once at admission. The subpopulation of AF after AFL was also captured (ICD-9-CM: 427.31). The diagnostic codes of both AFL and AF have been validated in previous NHIRD studies.

Study design

A total of 35 353 patients with AFL between 1 January 2001 and 31 December 2013 were identified for this study. Patients who had missing information or who were <20 years old were excluded. In order to evaluate the post-AFL incidence of AF, patients who were diagnosed with AF prior to the AFL diagnostic date or simultaneously were excluded. Since catheter ablation of AFL may influence the occurrence of AF, patients who received catheter ablation for AFL during follow-up were also excluded. At last, 17 620 patients with AFL were eligible for analysis. The patients with AFL were classified into patients with solitary AFL (n=12 223) and patients with AFL-DAF (n=5397). For patients with AFL that developed AF within the last 3 years, the follow-up duration was from the AFL diagnostic date to the subsequent AF diagnostic date. For a solitary AFL patient, the end date of follow-up was assigned based on the AF diagnostic date of his/her counterpart in the solitary AFL group using PSM. The differences in clinical characteristics and in the scores of interest between groups were evaluated using the absolute value of the standardised difference (STD), where an absolute value of less than 0.1 (−0.1 to 0.1) indicates a negligible difference, an absolute value ranging from 0.1 to 0.2 represents a moderate difference, and an absolute value exceeding 0.2 means a substantial difference.

The follow-up and delta scores of the CHA\textsubscript{DS}\textsubscript{2}-VASc and the proposed A\textsubscript{C}\textsubscript{S}\textsubscript{2}-VASc were used to predict the risk of subsequent AF development. Using the 0 score subgroup as the reference category, the relative risk and corresponding 95% CIs were calculated for each score greater than 0. The area under the curve (AUC), integrated discrimination index (IDI) and net reclassification index (NRI) were used to evaluate the performance of discriminating a subsequent occurrence of ischaemic stroke (defined as the principal diagnosis of hospitalisation) for the matched patients with AFL between the follow-up and delta scores and between the CHA\textsubscript{DS}\textsubscript{2}-VASc and the proposed A\textsubscript{C}\textsubscript{S}\textsubscript{2}-VASc scores. A p value of <0.05 was considered statistically significant. Data analysis was conducted using commercial software (SAS V.9.4).
Arrhythmias and sudden death

since this study is a retrospective cohort study based on Taiwan national insurance database, in no part or stage of the research were the patients/public involved.

**RESULTS**

**Patient inclusion**

A total of 17,620 patients were included in the study. Among them, 12,223 had solitary AFL and 5,397 developed AF during follow-up (mean and median duration: 0.81 and 0.47 years, respectively). Then, a 1:1 PSM with age group, gender, baseline CHA2DS2-VASc score and diagnosed year of AFL was carried out. Moreover, the index date of a patient in the solitary AFL group was assigned based on a counterpart in the AFL-DAF group. Finally, 4,101 patients with solitary AFL and 4,101 patients with AFL-DAF were eligible for analysis (figure 1).

**Baseline characteristics of patients with solitary AFL and patients with AFL-DAF**

The baseline characteristics of the patients with solitary AFL and those with AFL-DAF before and after PSM are shown in table 1. There was no substantial difference between groups after PSM, and all the absolute values of STD were less than 0.1. The distribution of duration from the index date to the end of follow-up between groups before and after PSM can be seen in online supplemental figure 1. The distribution pattern was very similar between groups after PSM.

**CHA2DS2-VASc components at baseline, during follow-up, and delta values between patients with solitary AFL and patients with AFL-DAF**

At baseline, there were no differences between groups. During the 3-year follow-up, the patients with AFL-DAF had more HF, stroke/TIA, and vascular disease, and higher CHA2DS2-VASc scores (STD values <−0.1). Since the group differences in incremental prevalence of HF and stroke/TIA was substantial (STD values <−0.2), that of vascular disease was moderate (STD values ranged from −0.2 to −0.1), and that of diabetes and hypertension was negligible (STD values ranged from −0.1 to 0.1), we reweighted the component of HF as 2 (the same with stroke/TIA), vascular disease as 1, and diabetes/hypertension as none in the proposed A2C2S2-VASc score (table 2).

Therefore, the A2C2S2-VASc score was (age ≥75 (doubled), CHF (doubled), stroke (doubled), vascular disease, age 65–74 and sex category (female)). The follow-up A2C2S2-VASc score and delta A2C2S2-VASc score were substantially higher in patients with AFL-DAF than
Table 1  Baseline characteristics of study patients before and after propensity score matching

| Variables                                      | All patients | Propensity score matched |   |   |
|-----------------------------------------------|--------------|--------------------------|---|---|
| CHA2DS2-VA Sc components                      | All patients | Propensity score matched |   |   |
| Female sex                                    | 4867 (39.8)  | 2060 (38.2)              | 0.03 | 1570 (38.3) | 1570 (38.3) | <0.01 |
| Age (years)                                   | 68.7±14.9    | 71.3±12.5                | -0.19 | 70.1±12.5 | 70.4±12.5 | -0.02 |
| Age group                                     |             |                         |   |   |
| <65 (score 0)                                 | 4225 (34.6)  | 1458 (27.0)              | 0.16 | 1212 (29.6) | 1212 (29.6) | <0.01 |
| 65–74 (score 1)                               | 3175 (26.0)  | 1533 (28.4)              | -0.06 | 1201 (29.3) | 1201 (29.3) | <0.01 |
| ≥75 (score 2)                                 | 4823 (39.5)  | 2406 (44.6)              | -0.10 | 1688 (41.2) | 1688 (41.2) | <0.01 |
| Heart failure                                 | 1622 (13.3)  | 916 (17.0)               | -0.10 | 492 (12.0) | 521 (12.7) | -0.02 |
| Hypertension                                  | 6987 (57.2)  | 3231 (59.9)              | -0.06 | 2383 (58.1) | 2382 (58.1) | <0.01 |
| Diabetes mellitus                             | 2295 (18.8)  | 999 (18.5)               | 0.01 | 771 (18.8) | 677 (16.5) | 0.06 |
| Stroke/thromboembolism                        | 1829 (15.0)  | 848 (15.7)               | -0.02 | 530 (12.9) | 547 (13.3) | -0.01 |
| Ischaemic stroke                              | 1611 (13.2)  | 749 (13.9)               | -0.02 | 475 (11.6) | 486 (11.9) | -0.01 |
| Systemic thromboembolism                      | 172 (1.4)    | 93 (1.7)                 | -0.03 | 34 (0.8) | 61 (1.5) | -0.06 |
| Venous thromboembolism                        | 133 (1.1)    | 43 (0.8)                 | 0.03 | 35 (0.9) | 24 (0.6) | 0.03 |
| Vascular disease                              | 4529 (37.1)  | 2273 (42.1)              | -0.10 | 1658 (40.4) | 1690 (41.2) | -0.02 |
| Myocardial infarction                          | 647 (5.3)    | 263 (4.9)                | 0.02 | 199 (4.9) | 176 (4.3) | 0.03 |
| Peripheral arterial disease                   | 316 (2.6)    | 135 (2.5)                | 0.01 | 166 (4.0) | 176 (4.3) | -0.01 |
| Ischaemic heart disease                       | 4284 (35.0)  | 2172 (40.2)              | -0.11 | 1557 (38.0) | 1583 (38.6) | -0.01 |
| CHA2DS2-VA Sc score                           | 3.0±1.8      | 3.2±1.8                  | -0.13 | 3.1±1.7 | 3.1±1.7 | <0.01 |
| CHA2DS2-VA Sc score classification            |             |                         |   |   |
| 0                                             | 923 (7.6)    | 353 (6.5)                | 0.04 | 305 (7.4) | 305 (7.4) | <0.01 |
| 1                                             | 1920 (15.7)  | 582 (10.8)               | 0.15 | 506 (12.3) | 506 (12.3) | <0.01 |
| 2                                             | 2267 (18.5)  | 976 (18.1)               | 0.01 | 776 (18.9) | 776 (18.9) | <0.01 |
| 3                                             | 2428 (19.9)  | 1168 (21.6)              | -0.04 | 916 (22.3) | 916 (22.3) | <0.01 |
| 4                                             | 2178 (17.8)  | 1016 (18.8)              | -0.03 | 780 (19.0) | 780 (19.0) | <0.01 |
| 5                                             | 1340 (11.0)  | 693 (12.8)               | -0.06 | 478 (11.7) | 478 (11.7) | <0.01 |
| 6                                             | 688 (5.6)    | 382 (7.1)                | -0.06 | 218 (5.3) | 218 (5.3) | <0.01 |
| 7                                             | 350 (2.9)    | 169 (3.1)                | -0.02 | 94 (2.3) | 94 (2.3) | <0.01 |
| 8                                             | 110 (0.9)    | 44 (0.8)                 | 0.01 | 23 (0.6) | 23 (0.6) | <0.01 |
| 9                                             | 19 (0.2)     | 14 (0.3)                 | -0.02 | 5 (0.1) | 5 (0.1) | <0.01 |
| COPD (included in HATCH score)                | 2223 (18.2)  | 1117 (20.7)              | -0.06 | 712 (17.4) | 797 (19.4) | -0.05 |
| HATCH score*                                  | 1.6±1.3      | 1.7±1.3                  | -0.12 | 1.5±1.3 | 1.6±1.3 | -0.03 |
| HATCH score classification                    |             |                         |   |   |
| 0                                             | 2764 (22.6)  | 964 (17.9)               | 0.12 | 867 (21.1) | 842 (20.5) | 0.02 |
| 1                                             | 3965 (32.4)  | 1707 (31.6)              | 0.02 | 1387 (33.8) | 1367 (33.3) | 0.01 |
| 2                                             | 2806 (23.0)  | 1346 (24.9)              | -0.05 | 1038 (25.3) | 1028 (25.1) | 0.01 |
| 3                                             | 1461 (12.0)  | 771 (14.3)               | -0.07 | 478 (11.7) | 505 (12.3) | -0.02 |
| 4                                             | 843 (6.9)    | 425 (7.9)                | -0.04 | 234 (5.7) | 265 (6.5) | -0.03 |
| 5                                             | 323 (2.6)    | 150 (2.8)                | -0.01 | 80 (2.0) | 80 (2.0) | <0.01 |
| 6                                             | 61 (0.5)     | 34 (0.6)                 | -0.02 | 17 (0.4) | 14 (0.3) | 0.01 |
| Other comorbidities                           |             |                         |   |   |
| Dyslipidaemia                                  | 1478 (12.1)  | 607 (11.2)               | 0.03 | 494 (12.0) | 439 (10.7) | 0.04 |
| Gout                                          | 1246 (10.2)  | 623 (11.5)               | -0.04 | 460 (11.2) | 464 (11.3) | <0.01 |
| Renal function status                         |             |                         |   |   |
| Normal                                        | 10 449 (85.5) | 4672 (86.6)              | -0.03 | 3565 (86.9) | 3594 (87.6) | -0.02 |

Continued
in those with solitary AFL (STD values <−0.2). Furthermore, the CHA2DS2-VASc and A2C2S2-VASc scores during follow-up were significantly higher in the AFL-DAF group than in the solitary AFL group (figure 2A). And, the delta score of CHA2DS2-VASc and the A2C2S2-VASc score were significantly higher in the AFL-DAF group than in the solitary AFL group (figure 2B).

Distribution of components for the CHA2DS2-VASc score and the A2C2S2-VASc score between patients with solitary AFL and patients with AFL-DAF

The distribution of delta CHA2DS2-VASc scores in the solitary AFL group and the AFL-DAF group showed the percentage of delta scores ≥1 was higher in the AFL-DAF group than in the solitary AFL group (50.3% vs 32.1%) (figure 3A). The distribution of delta A2C2S2-VASc scores in the solitary AFL group and the AFL-DAF group also showed that the percentage of delta scores ≥1 was higher in the AFL-DAF group than in the solitary AFL group (45.2% vs 25.8%) (figure 3B).

Predicting development of AF using the CHA2DS2-VASc score and the A2C2S2-VASc score in patients with AFL

The event rate of AF development at different levels of follow-up CHA2DS2-VASc scores and follow-up A2C2S2-VASc scores can be seen in figure 4A. The risks of AF development in patients with follow-up CHA2DS2-VASc scores ≥2 and in patients with follow-up scores ≥3 in the proposed A2C2S2-VASc score were significantly higher than in patients with follow-up scores of 0. The effect size (relative risks) at each level of score ≥1 was similar between these two scores. Figure 4B shows the event rate of AF development at different levels of delta CHA2DS2-VASc scores and delta A2C2S2-VASc scores. The relative risk of AF development in patients with scores ≥1 in both the delta CHA2DS2-VASc and delta A2C2S2-VASc scoring

| Variables                      | All patients | Propensity score matched |
|-------------------------------|--------------|--------------------------|
|                               | Solitary AFL (n=12223) | AFL then AF (n=5397) | STD | Solitary AFL (n=4101) | AFL then AF (n=4101) | STD |
| Non-dialysis CKD              | 1380 (11.3)  | 590 (10.9)              | 0.01 | 421 (10.3)  | 409 (10.0)              | 0.01 |
| Dialysis                      | 394 (3.2)    | 135 (2.5)               | 0.04 | 115 (2.8)    | 98 (2.4)                | 0.03 |
| Immune disease                | 232 (1.9)    | 105 (1.9)               | <0.01| 92 (2.2)     | 80 (2.0)                | 0.02 |
| Abnormal liver function       | 1408 (11.5)  | 605 (11.2)              | 0.01 | 458 (11.2)   | 462 (11.3)              | <0.01|
| Malignancy                    | 952 (7.8)    | 378 (7.0)               | 0.03 | 260 (6.3)    | 289 (7.0)               | −0.03|

Continuous data are presented as mean±SD.

AF, atrial fibrillation; AFL, atrial flutter; SE, thromboembolism; STD, standardised mean difference.
systems was significantly higher than in patients with a delta score of 0. The effect size (relative risks) at the level of a score ≥ 2 was slightly higher in the delta A2C2S2-VASc than in the delta CHA2DS2-VASc scoring systems.

Performance of the CHA2DS2-VASc score and the A2C2S2-VASc score in discriminating subsequent occurrence of ischaemic stroke

Finally, we compared the delta score to the follow-up, and the proposed A2C2S2-VASc score to the CHA2DS2-VASc score in discriminating the subsequent occurrence of ischemic stroke in the 8202 matched patients with AFL. The AUC increment, the IDI and NRI were significantly greater in the delta score than in the follow-up score for both the CHA2DS2-VASc and A2C2S2-VASc scores. The results indicated that the AUC increment, the IDI and NRI were significantly greater in the A2C2S2-VASc score than in the CHA2DS2-VASc score using both the follow-up and the delta scores (table 3).

DISCUSSION

There are several important findings in this study. First, the percentages of new-onset CHF, stroke/TIA and peripheral artery disease were different in patients with solitary AFL and those with AFL-DAF. Second, the incidence of AF development was higher in patients with AFL who developed AF during follow-up than in those who did not have AF development. Our study also showed that the relative risk of new-onset CHF in patients developing AF was the same as that of new-onset stroke in patients with AFL, and was higher than that of developing new-onset vascular disease. Those patients with AFL at a low level of CHA2DS2-VASc who suffered from these diseases during follow-up should accept more aggressive monitoring and follow-up in the

Figure 2 The mean CHA2DS2-VASc and proposed A2C2S2-VASc scores of patients with solitary AFL and AFL then AF. (A) Follow-up score of both scoring systems. (B) Delta score of both scoring systems. The error bar represents the SD. AF, atrial fibrillation; AFL, atrial flutter; STD, standardised difference.

Figure 3 Distribution of components for the delta CHA2DS2-VASc score (A) and the delta A2C2S2-VASc score (B) between solitary AFL and AFL developing into patients with AF. AF, atrial fibrillation; AFL, atrial flutter.

Risk factors for patients with AFL developing AF during follow-up

According to the Framingham heart study follow-up data and also the meta-analysis, several risk factors, including male sex, ageing, hypertension, CHF, coronary artery disease, valvular heart disease and diabetes mellitus were associated with AF development. Among these risk factors, CHF, male sex and coronary artery disease were the three strongest risk factors for predicting the development of AF. In the present study, the incidence of new-onset CHF, stroke and vascular disease was higher in patients with AFL who developed AF during follow-up than in those who did not have AF development. Our study also showed that the relative risk of new-onset CHF in patients developing AF was the same as that of new-onset stroke in patients with AFL, and was higher than that of developing new-onset vascular disease. Those patients with AFL at a low level of CHA2DS2-VASc who suffered from these diseases during follow-up should accept more aggressive monitoring and follow-up in the
diagnosis of AF, because the strategy of OAC use and clinical outcome might be different.

**Scoring systems for predicting development of AF in patients with AFL**

Some scoring systems, including the CHA2DS2-VASc score, have been used to predict new-onset AF in typical patients with AFL receiving catheter ablation for CTI, and also to predict long-term mortality in typical AFL.\(^7\)\(^8\)\(^17\)\(^18\) To the best of our knowledge, there is no scoring system to predict AF and stroke development in patients with AFL. Our study, using a large nationwide database, reveals the independent risk factors for AF occurrence during follow-up in patients with AFL. Our study also showed that both the follow-up score and the delta score of both scoring systems can predict AF development in patients with AFL. In addition, the delta scoring system is stronger than the follow-up scoring system in predicting AF development. A delta score ≥3 was more powerful than a follow-up score ≥5, and indicated an at least 1.6-fold increased risk of developing AF. Therefore, closely monitoring and following up patients with AFL who have a new-onset of comorbidities to detect the occurrence of AF is as important as the management of the comorbidity itself, particularly a new attack of HF and stroke.

**Comparing the ability of scoring systems to predict the development of ischaemic stroke in patients with AFL**

According to our study, the A2C2S2-VASc follow-up score was better than the CHA2DS2-VASc score in predicting ischaemic stroke development in patients with AFL, and there was no difference in the delta score of both scoring systems in predicting ischaemic stroke. Even more, the delta score was a stronger predictor of ischaemic stroke than the follow-up score in both scoring systems, and the delta score had improved NRI compared with the follow-up score. A previous study showed that the CHA2DS2-VASc score was not static in the AF cohort, and that stroke risk in patients with AF is a dynamic process due to increasing age and incident comorbidities.\(^19\) Our study emphasised that the risk of ischaemic stroke in patients with AFL may continuously increase, and that regularly reassessing the scoring systems and the strategy of stroke prevention during follow-up in these patients with AFL are also important.

**Study limitations**

There are some limitations in this retrospective insurance database study. First, the subtype of AFL was not recorded in the NHIRD database. So, we could not

---

**Figure 4** Relative risk of predicting atrial flutter developing AF using different follow-up scores (A) and delta scores (B) of the CHA2DS2-VASc scoring system and the proposed A2C2S2-VASc scoring system. AF, atrial fibrillation.

**Table 3** Comparison of delta score to the follow-up score as well as the proposed A2C2S2-VASc score to CHA2DS2-VASc score for discriminating a subsequent occurrence of ischaemic stroke in the 8202 matched patients with atrial flutter

| Score | AUC, % (95% CI) | Delta AUC, % (95% CI) | IDI, % (95% CI) | Category-free NRI, % (95% CI) |
|-------|----------------|----------------------|----------------|-----------------------------|
| CHA2DS2-VASc | | | | |
| Follow-up | 55.6 (54.4 to 56.8) | Reference | Reference | Reference |
| Delta | 60.2 (59.1 to 61.3) | 4.60 (3.23 to 5.96) | 2.97 (2.56 to 3.37) | 25.9 (21.6 to 30.1) |
| Proposed A2C2S2-VASc | | | | |
| Follow-up | 57.9 (56.7 to 59.2) | Reference | Reference | Reference |
| Delta | 61.0 (60.0 to 62.0) | 3.05 (1.84 to 4.27) | 3.40 (2.96 to 3.84) | 22.2 (17.9 to 26.5) |
| Follow-up | 55.6 (54.4 to 56.8) | Reference | Reference | Reference |
| Proposed A2C2S2-VASc | 57.9 (56.7 to 59.2) | 2.34 (1.80 to 2.87) | 0.93 (0.79 to 1.06) | 25.6 (21.3 to 29.8) |
| Delta | 60.2 (59.1 to 61.3) | 0.79 (0.31 to 1.27) | 1.36 (1.13 to 1.59) | 35.4 (31.9 to 38.9) |

All the results were significant at a p<0.001 level. AUC, area under the curve; IDI, integrated discrimination index; NRI, net reclassification index.
clearly classify the types of AFL (neither CTI vs non-CTI flutter, nor left-side AFL vs right-side AFL), which may also have an impact on the occurrence of AF during follow-up. However, we could not confirm the actual type and mechanism of AFL in those patients who did not receive ablation, and the success or failure of ablation could also influence the occurrence of AF thereafter. So, this study evaluated the potential risks of AF development in all patients with AFL, including those patients who did not receive ablation. Second, although our study, using the CHA2DS2-VASc score and also the reweighted A2C2S2-VASc score, showed patients with a higher score had a higher risk of AF development, we did not evaluate the anticoagulation status or other medications used for disease control and risk modification before and after AF development. We could not evaluate the quality of care provided for other new-onset comorbidities before the diagnosis of AF or the use and adherence to anticoagulation medications after the diagnosis of AF, which may influence not only the risk of AF development, but also the risk of ischemic stroke.

CONCLUSIONS

This national cohort study showed that new-onset CHF, stroke/TIA and vascular disease were predictors of AF development in patients with AFL. Patients with AFL and delta scores ≥1 in both the CHA2DS2-VASc and A2C2S2-VASc scoring systems had a higher risk of AF development during follow-up. Meanwhile, patients with AFL and a follow-up score ≥2 in the CHA2DS2-VASc and ≥3 in the A2C2S2-VASc scoring systems also had a higher risk of AF development during follow-up. The delta score was better than the follow-up score in both scoring systems in predicting ischemic stroke during follow-up. Patients with AFL at a low level of CHA2DS2-VASc should be closely followed up when a newly developed comorbidity of a component of the CHA2DS2-VASc is noted thereafter.

Acknowledgements

The authors thank Zee Ya-Jhu Syu and Alfred Hsing-Fen Lin for their assistance in statistical analysis.

Contributors

Y-LC, H-TW and Y-SL contributed to the conception or design of the work and final approval of the version to be published. Y-LC and Y-SL contributed to the data collection. H-CC, W-HL, S-ZC, S-KH and C-MC contributed to the data analysis and interpretation. Y-LC, H-TW and Y-SL drafted the article. H-CC, W-HL, S-ZC, S-KH and C-MC contributed to the critical revision of the article.

Funding

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests

None declared.

Patient consent for publication

Not required.

Ethics approval

This study was approved by the Institutional Review Board of Chang Gung Memorial Hospital (202000961B1). The dataset used in this study is held by the Taiwan Ministry of Health and Welfare (MOHW). Any researcher interested in accessing this dataset can submit an application form to the MOHW requesting access (email: stcarolwu@mohw.gov.tw).

Provenance and peer review

Not commissioned; internally peer reviewed.

Data availability statement

Data are available upon reasonable request. The dataset used in this study is held by the Taiwan Ministry of Health and Welfare (MOHW). Any researcher interested in accessing this dataset can submit an application form to the MOHW requesting access (email: stcarolwu@mohw.gov.tw).

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 United States license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs

Yung-Lung Chen http://orcid.org/0000-0001-9706-4534
Yu-Shen Lin http://orcid.org/0000-0001-9706-4534

REFERENCES

1 Lin Y-S, Chen Y-L, Chen T-H, et al. Comparison of clinical outcomes among patients with atrial fibrillation or atrial flutter stratified by CHA2DS2-VASc score. *JAMA Netw Open* 2018;1:e180894.
2 Lin Y-S, Chen T-H, Chi C-C, et al. Different implications of patient initial failure, ischemic stroke, and mortality between nonvalvular atrial fibrillation and atrial Flutter-a view from a national cohort study. *J Am Heart Assoc* 2017;6. doi:10.1161/JAHA.117.006406. [Epub ahead of print: 21 Jul 2017].
3 Chen Y-L, Lin Y-S, Wang H-T, et al. Clinical outcomes of solitary atrial flutter patients using anticoagulation therapy: a national cohort study. *European* 2019;21:313–21.
4 Biblo LA, Yuan Z, Quan KJ, et al. Risk of stroke in patients with atrial flutter. *Am J Cardiol* 2001;87:346–9.
5 Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. *Chest* 2010;137:263–72.
6 Koren J, Hindricks G, Koeiliuk J, et al. Comparison of CHADS2, CHA2DS2-VASc, and CHA2DS2-VASc2 scores for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation: the Leipzig heart center AF ablation registry. *Circ Arrhythm Electrophysiol* 2014;7:281–7.
7 Pérez FJ, Schubert CM, Parvez B, et al. Long-term outcomes after catheter ablation of cavo-tricuspid isthmus dependent atrial flutter: a meta-analysis. *Circ Arrhythm Electrophysiol* 2009;2:393–401.
8 Jin MN, Song C, Kim TH, et al. CHA2DS2-VASc score in the prediction of ischemic stroke in patients after radiofrequency catheter ablation of typical atrial flutter. *Yonsei Med J* 2018;59:236–42.
9 Chang C-H, Lee Y-C, Tsai C-T, et al. Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease. *Atherosclerosis* 2014;232:224–30.
10 Cheng C-L, Lee C-H, Chen P-S, et al. Validation of acute myocardial infarction cases in the National health insurance research database in Taiwan. *J Epidemiol* 2014;24:500–7.
11 Hsieh C-Y, Chen C-H, Li C-Y, et al. Validating the diagnosis of acute ischemic stroke in a national health insurance claims database. *J Formos Med Assoc* 2012;111:524–5.
12 Sung S-F, Hsieh C-Y, Lin H-J, et al. Validation of algorithms to identify stroke risk factors in patients with acute ischemic stroke, transient ischemic attack, or intracerebral hemorrhage in an administrative claims database. *Int J Cardiol* 2016;215:277–82.
13 Wu C-S, Lai M-S, Gau SS-F, et al. Concordance between patient self-reports and claims data on clinical diagnoses, medication use, and health system utilization in Taiwan. *PLoS One* 2014;9:e112257.
14 Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. *J Clin Epidemiol* 2001;54:387–98.
15 Lau DH, Nattel S, Kalmann JM, et al. Modifiable risk factors and atrial fibrillation. *Circulation* 2017;136:583–96.
16 Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham heart study. *JAMA* 1994;271:840–4.
17 Garcia Seara J, Gude F, Rapooseras-Roubin S, et al. Long-term outcome prediction of CHA2DS2VASc and hatch scores in a cohort of patients with typical atrial flutter. *Int J Cardiol* 2015;199:426–8.
18 Chen K, Bai R, Deng W, et al. HATCH score in the prediction of new-onset atrial fibrillation after catheter ablation of typical atrial flutter. *Heart Rhythm* 2015;12:1483–9.
19 Chao T-F, Lip GYH, Liu C-J, et al. Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation. *J Am Coll Cardiol* 2018;71:122–32.